Inhibiting Sec61 with cotransin increased the surface expression of BCMA by MM cell lines, resulting in enhanced efficacy a BCMA‐targeting antibody–drug conjugate (Ramkumar et al, 2020). The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.